The Medicaid Cost of Palivizumab
نویسندگان
چکیده
1. Grohskopf LA, Shay DK, Shimabukuro TT, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2013–14 influenza season. MMWR Recomm Rep 2013; 62:1–43. 2. Varricchio F, Iskander J, DeStefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287–94. 3. Halsey NA, Edwards KM, Decker CL, et al. Algorithm to assess causality after individual adverse event following immunizations. Vaccine 2012; 30:5791–8. 4. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. Available at: http://www.who.int/vaccine_safety/ publications/aevi_manual.pdf. Accessed November 13, 2014. 5. Smith JC, Snider DE, Pickering LK, Advisory Committee on Immunization Practices. Immunization policy development in the United States: the role of the Advisory Committee on Immunization Practices. Ann InternMed 2009; 150:45–9. 6. Smith JC, Hinman AR, Pickering LK. History and evolution of the Advisory Committee on Immunization Practices— United States, 1964–2014. MMWR Morb Mortal Wkly Rep 2014; 63:955–8. 7. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014–15 influenza season. MMWR Recomm Rep 2014; 63:691–7.
منابع مشابه
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
OBJECTIVE Use of palivizumab prophylactic therapy reduces the occurrence of hospitalizations for serious respiratory syncytial virus (RSV) lower respiratory tract infections in at-risk infants. The direct cost-benefit of palivizumab prophylaxis for infants who are born at 32 to 35 weeks' estimated gestational age (EGA) during their first year of life has not been systematically examined. The ob...
متن کاملTrends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
INTRODUCTION Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes outpatient palivizumab utilization trends and characterizes high-risk infants receiving palivizumab w...
متن کاملUtilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
A survey conducted in December 2008 of 69 health plans representing over 83 million commercial, Medicare, and managed Medicaid members found that 81% of the health plans required prior authorization (PA) for coverage of palivizumab (Synagis).1 Palivizumab is commonly covered under the medical benefit (73%) rather than the pharmacy benefit, and is ranked among the therapeutic areas with the high...
متن کاملMedical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections and hospitalization in infants. Palivizumab is currently the only available agent for prevention of RSV infection in high-risk infants. This high-cost injectable requires monthly dosing during the RSV season. Compliance with the injection schedule is important in the prevention of RSV infecti...
متن کاملPartial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis
BACKGROUND Infection with respiratory syncytial virus (RSV) is common among young children insured through Medicaid in the United States. Complete and timely dosing with palivizumab is associated with lower risk of RSV-related hospitalizations, but up to 60% of infants who receive palivizumab in Medicaid population do not receive full prophylaxis. The purpose of this study was to evaluate the a...
متن کاملImpact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children.
OBJECTIVES To determine the impact of prophylactic therapy for respiratory syncytial virus (RSV) infections on subsequent hospitalizations and related lengths of stay and costs and to estimate whether prophylactic treatment was cost-effective. DESIGN Retrospective cohort study of the 1999-2000 RSV season. Propensity scores were used to identify an untreated comparison group to adjust for trea...
متن کامل